UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2025

Commission File Number: 001-31368

 

 

SANOFI

(Translation of registrant’s name into English)

 

 

46, avenue de la Grande Armée, 75017 Paris, FRANCE

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

 

 

 

In January 2025, Sanofi published the press releases attached hereto as Exhibits 99.1 and 99.2 which are incorporated herein by reference.

Exhibit Index

 

Exhibit  No.		Description
Exhibit 99.1		Press Release dated January 9, 2025 : New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
Exhibit 99.2		Press Release dated January 13, 2025 : Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: January 14, 2025						SANOFI
				By		/s/ Alexandra Roger
				Name:		Alexandra Roger
				Title:		Head of Legal Corporate & Finance

 

3